Eric Winquist
London Health Sciences Centre · London Regional Cancer Program · University Health Network Princess Margaret Cancer Center P2C
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Winquist as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:47 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02813226 · Assessment of New Molecular Imaging Strategies for Prostate CancerOntario Clinical Oncology Group (OCOG) · completed · Prostate Cancer · principal investigator
- N/ANCT02752932 · TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility StudyLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · completed · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT02196168 · Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck CancerNational Cancer Institute (NCI) · terminated · Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma · principal investigator
- N/ANCT02121600 · 18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate CancerLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · terminated · Prostate Cancer · principal investigator
- Ph2NCT00516841 · A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal CancerFacet Biotech · terminated · Ovarian Cancer, Peritoneal Neoplasms · principal investigator
- Ph2NCT00327340 · Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCAchieve Life Sciences · completed · Prostate Cancer · principal investigator
- Ph2NCT00095628 · SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerNational Cancer Institute (NCI) · completed · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer · principal investigator
- Ph2NCT00066352 · Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterUniversity Health Network, Toronto · completed · Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:47 UTC. The ranking covers the 200 most relevant of 77 PubMed records, and a shared surname and initials can bring in a namesake. All 77 on PubMed
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- 1,529 citationsRCR 42.3
- 1,503 citationsRCR 81.7
- Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.N Engl J Med · 20071,272 citationsRCR 32.7
- Exemestane for breast-cancer prevention in postmenopausal women.N Engl J Med · 2011712 citationsRCR 18.2
- 581 citationsRCR 12.8
- Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.Lancet Oncol · 2019386 citationsRCR 21.0
- Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.J Clin Oncol · 2010369 citationsRCR 8.3
- 361 citationsRCR 9.3
- 341 citationsRCR 9.7